Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Nov;30(5):761–767. doi: 10.1111/j.1365-2125.1990.tb03847.x

The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.

M D Coleman 1, A K Scott 1, A M Breckenridge 1, B K Park 1
PMCID: PMC1368178  PMID: 2271376

Abstract

1. The N-hydroxylation of dapsone is thought to be responsible for the methaemoglobinaemia and haemolysis associated with this drug. We wished to investigate the effect of concurrent administration of cimetidine (400 mg three times per day) on the disposition of a single dose (100 mg) of dapsone in seven healthy volunteers in order to inhibit selectively N-hydroxylation. 2. The AUC of dapsone (31.0 +/- 7.2 micrograms ml-1 h) was significantly increased (P less than 0.001) in the presence of cimetidine (43.3 +/- 8.8 micrograms ml-1 h). 3. Peak methaemoglobin levels observed after dapsone administration (2.5 +/- 0.6%) were significantly (P less than 0.05) reduced in the presence of cimetidine (0.98 +/- 0.35%). 4. The percentage of the dose excreted in urine as the glucuronide of dapsone hydroxylamine was significantly (P less than 0.05) reduced in the presence of cimetidine (34.2 +/- 9.3 vs 23.1 +/- 4.2%). 5. Concurrent cimetidine therapy might reduce some of the haematological side-effects of dapsone.

Full text

PDF
761

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam A. M., Rogers H. J., Amiel S. A., Rubens R. D. The effect of acetylator phenotype on the disposition of aminoglutethimide. Br J Clin Pharmacol. 1984 Oct;18(4):495–505. doi: 10.1111/j.1365-2125.1984.tb02497.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Coleman M. D., Breckenridge A. M., Park B. K. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol. 1989 Oct;28(4):389–395. doi: 10.1111/j.1365-2125.1989.tb03517.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Coleman M. D., Hoaksey P. E., Breckenridge A. M., Park B. K. Inhibition of dapsone-induced methaemoglobinaemia in the rat isolated perfused liver. J Pharm Pharmacol. 1990 May;42(5):302–307. doi: 10.1111/j.2042-7158.1990.tb05416.x. [DOI] [PubMed] [Google Scholar]
  4. Coleman M. D., Winn M. J., Breckenridge A. M., Park B. K. Inhibition of dapsone-induced methaemoglobinaemia in the rat. Biochem Pharmacol. 1990 Feb 15;39(4):802–805. doi: 10.1016/0006-2952(90)90164-g. [DOI] [PubMed] [Google Scholar]
  5. Cucinell S. A., Israili Z. H., Dayton P. G. Microsomal N-oxidation of dapson as a cause of methemoglobin formation in human red cells. Am J Trop Med Hyg. 1972 May;21(3):322–331. doi: 10.4269/ajtmh.1972.21.322. [DOI] [PubMed] [Google Scholar]
  6. Degowin R. L., Eppes R. B., Powell R. D., Carson P. E. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate-dehydrogenase deficiency. Bull World Health Organ. 1966;35(2):165–179. [PMC free article] [PubMed] [Google Scholar]
  7. Feely J., Pereira L., Guy E., Hockings N. Factors affecting the response to inhibition of drug metabolism by cimetidine--dose response and sensitivity of elderly and induced subjects. Br J Clin Pharmacol. 1984 Jan;17(1):77–81. doi: 10.1111/j.1365-2125.1984.tb05002.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Ganer A., Knobel B., Fryd C. H., Rachmilewitz E. A. Dapsone-induced methemoglobinemia and hemolysis in the presence of familial hemoglobinopathy Hasharon and familial methemoglobin reductase deficiency. Isr J Med Sci. 1981 Aug;17(8):703–704. [PubMed] [Google Scholar]
  9. Gelber R., Peters J. H., Gordon G. R., Glazko A. J., Levy L. The polymorphic acetylation of dapsone in man. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):225–238. doi: 10.1002/cpt1971122part1225. [DOI] [PubMed] [Google Scholar]
  10. Green S. T., Goldberg D. J., Leach J., Christie P. R., Kennedy D. H. AIDS-related Pneumocystis carinii pneumonia successfully treated with dapsone-trimethoprim. Br J Clin Pharmacol. 1988 Oct;26(4):487–488. doi: 10.1111/j.1365-2125.1988.tb03411.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Grindulis K. A., McConkey B. Rheumatoid arthritis: the effects of treatment with dapsone on hemoglobin. J Rheumatol. 1984 Dec;11(6):776–778. [PubMed] [Google Scholar]
  12. Grossman S. J., Jollow D. J. Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia. J Pharmacol Exp Ther. 1988 Jan;244(1):118–125. [PubMed] [Google Scholar]
  13. Halmekoski J., Mattila M. J., Mustakallio K. K. Metabolism and haemolytic effect of dapsone and its metabolites in man. Med Biol. 1978 Aug;56(4):216–221. [PubMed] [Google Scholar]
  14. Harrison J. H., Jr, Jollow D. J. Role of aniline metabolites in aniline-induced hemolytic anemia. J Pharmacol Exp Ther. 1986 Sep;238(3):1045–1054. [PubMed] [Google Scholar]
  15. Herve P., Tamayo E., Lenys R., Peters A., Rozenbaum A., Floris R. L. Kinetics of CFU-c population after autologous bone marrow graft. Br J Haematol. 1979 Dec;43(4):681–682. doi: 10.1111/j.1365-2141.1979.tb03803.x. [DOI] [PubMed] [Google Scholar]
  16. Horai Y., Ishizaki T. Rapid and sensitive liquid chromatographic method for the determination of dapsone and monoacetyldapsone in plasma and urine. J Chromatogr. 1985 Dec 13;345(2):447–452. doi: 10.1016/0378-4347(85)80187-0. [DOI] [PubMed] [Google Scholar]
  17. Hutchings A., Monie R. D., Spragg B., Routledge P. A. Acetylator phenotyping: the effect of ethanol on the dapsone test. Br J Clin Pharmacol. 1984 Jul;18(1):98–100. doi: 10.1111/j.1365-2125.1984.tb05029.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Israili Z. H., Cucinell S. A., Vaught J., Davis E., Lesser J. M., Dayton P. G. Studies of the metabolism of dapsone in man and experimental animals: formation of N-hydroxy metabolites. J Pharmacol Exp Ther. 1973 Oct;187(1):138–151. [PubMed] [Google Scholar]
  19. Kramer P. A., Glader B. E., Li T. K. Mechanism of methemoglobin formation by diphenylsulfones. Effect of 4-amino-4'-hydroxyaminodiphenylsulfone and other p-substituted derivatives. Biochem Pharmacol. 1972 May 1;21(9):1265–1274. doi: 10.1016/0006-2952(72)90288-2. [DOI] [PubMed] [Google Scholar]
  20. Levy L. Pharmacologic studies of clofazimine. Am J Trop Med Hyg. 1974 Nov;23(6):1097–1109. doi: 10.4269/ajtmh.1974.23.1097. [DOI] [PubMed] [Google Scholar]
  21. Manfredi G., De Panfilis G., Zampetti M., Allegra F. Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage. Br J Dermatol. 1979 Apr;100(4):427–432. doi: 10.1111/j.1365-2133.1979.tb01644.x. [DOI] [PubMed] [Google Scholar]
  22. Swain A. F., Ahmad R. A., Rogers H. J., Leonard J. N., Fry L. Pharmacokinetic observations on dapsone in dermatitis herpetiformis. Br J Dermatol. 1983 Jan;108(1):91–98. doi: 10.1111/j.1365-2133.1983.tb04583.x. [DOI] [PubMed] [Google Scholar]
  23. Teterissa M. R., Nathin M. A. Leprosy control in Indonesia. Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):511–513. [PubMed] [Google Scholar]
  24. Uetrecht J., Zahid N., Shear N. H., Biggar W. D. Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells. J Pharmacol Exp Ther. 1988 Apr;245(1):274–279. [PubMed] [Google Scholar]
  25. Venkatesan K., Bharadwaj V. P., Ramu G., Desikan K. V. Study on drug interactions. Lepr India. 1980 Apr;52(2):229–235. [PubMed] [Google Scholar]
  26. Weetman R. M., Boxer L. A., Brown M. P., Mantich N. M., Baehner R. L. In vitro inhibition of granulopoiesis by 4-amino-4'-hydroxylaminodiphenyl sulfone. Br J Haematol. 1980 Jul;45(3):361–370. doi: 10.1111/j.1365-2141.1980.tb07156.x. [DOI] [PubMed] [Google Scholar]
  27. Woosley R. L., Drayer D. E., Reidenberg M. M., Nies A. S., Carr K., Oates J. A. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med. 1978 May 25;298(21):1157–1159. doi: 10.1056/NEJM197805252982101. [DOI] [PubMed] [Google Scholar]
  28. Wright J. T., Jr, Goodman R. P., Bethel A. M., Lambert C. M. Cimetidine and dapsone acetylation. Drug Metab Dispos. 1984 Nov-Dec;12(6):782–783. [PubMed] [Google Scholar]
  29. Zuidema J., Hilbers-Modderman E. S., Merkus F. W. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet. 1986 Jul-Aug;11(4):299–315. doi: 10.2165/00003088-198611040-00003. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES